Applications of Multivariate Data Analysis in Biotech Processing - - BioPharm International

ADVERTISEMENT

Applications of Multivariate Data Analysis in Biotech Processing


BioPharm International
Volume 20, Issue 10


Figure 16. Loading plot (p[1] versus p[2])
To characterize the two products that have been successfully used for an antibody-producing cell culture process, principal component analysis was used. The data from a total of 17 lots—12 lots from vendor A (called product A) and 5 lots from vendor B (called product B)—were used for this analysis. The raw material type (product A or product B) was treated as a qualitative X variable and all the analytical data was used as continuous X data. The first principal component was able to explain 61% of variation in X data (R 2 X = 0.61), and this component was able to predict 54% of the variation in data (Q 2 = 0.54). The addition of a second principal component resulted in the cumulative goodness of fit (R 2 X) and predictability (Q 2 ) values of 0.77 and 0.50. Because the addition of second principal component decreased the model predictability to 0.50, this component was ignored and only the first component was used for analysis. The principal component analysis showed that the two products were distinct and belonged to different clusters in M-space. The correlation structure was analyzed using the loading plot. Product B, n-6 fatty acids, [n-6]:[n-3] ratio, and free fatty acids clustered together and appeared diagonally opposite to the cluster containing LDL, LDL:HDL, VLDL, VLDL:HDL, and PC. These results suggested that compared to product A, product B was richer in n-6 fatty acids and free fatty acids and had a higher [n-6]:[n-3] ratio. On the contrary, product A was richer in n-3 fatty acids and phosphatidylcholine. Product A also had a higher content of LDL and VLDL and had higher LDL:HDL and VLDL:HDL ratios compared to product B. It is likely that the dissimilarities between products A and B are due to the differences in starting sera that in turn may be related to the feeding practices of different herds used for serum production.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Despite AbbVie Snub, Shire Says it Will Double Sales by 2020
October 24, 2014
Manufacturing Challenges of mAb Production: CHO or Plant Cells?
October 24, 2014
Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials
October 23, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
Author Guidelines
Source: BioPharm International,
Click here